MiCo BioMed USA specializes in advanced immunoassay technologies, prominently featuring their Optimiser™ Technology. This innovative microfluidic approach significantly enhances the performance of immunoassay testing across various platforms, including diagnostics and life sciences. The Optimiser™ Technology is integrated into several products, such as the TROVA™ Point of Care Testing (POCT) system, which facilitates seamless assay transfers from traditional protocols and supports multiple ELISA methodologies. Additionally, the OptiMax™ STAT system leverages this technology to improve diagnostic throughput and flexibility in laboratory settings, while the OptiMax™ automation plates allow researchers to utilize existing reagents and automation systems, resulting in increased efficiency and reduced sample volumes.

The company also offers a range of assay solutions that utilize Optimiser™ Technology, including OptiMax™ Assay Kits and specific assay protocols designed for various ELISA applications. These protocols enable significant reductions in sample volume, with as little as 5 μl required, and can deliver results in just two hours. MiCo BioMed's Optimiser™ based protocols promise enhanced sensitivity and expanded dynamic ranges, allowing for 4 to 10 times more tests with the same amount of reagents. The company is committed to developing tailored protocols for specific research interests, further demonstrating their dedication to advancing immunoassay technologies in the life sciences sector.

United States

MiCo Biomed USA is a biotechnology company that offers Optimiser™ Plus Microfluidic Plates for Life Science and Diagnostic Immunoassays.

MiCo BioMed USA

Company Details